Related Experiment Videos
[Rheumatic disease and depression]
1Department of Neuropsychiatry, Yamagata University School of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|August 25, 2001
Summary
Depressive symptoms are common in rheumatic diseases like systemic lupus erythematosus (SLE), affecting about 30% of patients. Specific antibodies and brain imaging may help predict and manage these mood disorders.
Area of Science:
- Rheumatology
- Psychiatry
- Neurology
Background:
- Depressive symptoms frequently occur in patients with rheumatic diseases.
- Systemic lupus erythematosus (SLE) is often associated with depression, with a prevalence of approximately 30%.
Observation:
- In SLE, depressive symptoms typically last less than two months and often respond to antidepressants.
- Antibodies to ribosomal P protein may serve as a specific biomarker for SLE accompanied by depression.
- Neuroimaging techniques like single photon emission tomography (SPECT) and magnetic resonance imaging (MRI) show potential in predicting depressive symptom development.
Findings:
- A case of dermatomyositis with a manic-depressive state revealed reduced cerebral blood flow in the left frontal and temporal regions during depressive episodes.
- This suggests a potential link between localized cerebral blood flow and mood disturbances in certain rheumatic conditions.
Implications:
- Early identification of biomarkers and neuroimaging markers could lead to proactive management of depression in rheumatic disease patients.
- Understanding the neurobiological underpinnings of depression in rheumatic conditions may pave the way for targeted therapeutic strategies.